Czech National Bank Purchases 1,451 Shares of Axon Enterprise, Inc $AXON

Czech National Bank raised its position in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 6.8% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 22,942 shares of the biotechnology company’s stock after purchasing an additional 1,451 shares during the quarter. Czech National Bank’s holdings in Axon Enterprise were worth $12,862,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in AXON. Darwin Wealth Management LLC purchased a new position in shares of Axon Enterprise in the second quarter valued at about $37,000. Creative Financial Designs Inc. ADV purchased a new stake in shares of Axon Enterprise during the fourth quarter worth about $28,000. Sound Income Strategies LLC boosted its holdings in shares of Axon Enterprise by 550.0% during the fourth quarter. Sound Income Strategies LLC now owns 52 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 44 shares during the period. Camelot Portfolios LLC bought a new stake in shares of Axon Enterprise in the fourth quarter worth about $30,000. Finally, AlphaCentric Advisors LLC bought a new stake in shares of Axon Enterprise in the fourth quarter worth about $34,000. Institutional investors own 79.08% of the company’s stock.

Insiders Place Their Bets

In other news, insider Elizabeth Reid Coughlin sold 1,554 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $485.00, for a total transaction of $753,690.00. Following the sale, the insider owned 34,024 shares of the company’s stock, valued at $16,501,640. This trade represents a 4.37% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CRO Cameron Brooks sold 1,242 shares of Axon Enterprise stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $500.00, for a total transaction of $621,000.00. Following the completion of the sale, the executive owned 49,710 shares of the company’s stock, valued at $24,855,000. This represents a 2.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 58,989 shares of company stock worth $30,527,983 in the last quarter. Insiders own 4.20% of the company’s stock.

Axon Enterprise Stock Up 9.3%

Axon Enterprise stock opened at $571.01 on Friday. The firm has a market cap of $46.02 billion, a price-to-earnings ratio of 236.93, a PEG ratio of 11.65 and a beta of 1.39. The stock has a fifty day simple moving average of $513.80 and a two-hundred day simple moving average of $474.59. Axon Enterprise, Inc has a 12 month low of $339.01 and a 12 month high of $878.62. The company has a current ratio of 2.15, a quick ratio of 1.93 and a debt-to-equity ratio of 0.47.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported $1.88 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.84 by $0.04. The firm had revenue of $904.39 million for the quarter, compared to the consensus estimate of $876.42 million. Axon Enterprise had a return on equity of 2.84% and a net margin of 6.19%.The company’s quarterly revenue was up 35.3% on a year-over-year basis. During the same period in the prior year, the company posted $2.12 earnings per share. Equities analysts predict that Axon Enterprise, Inc will post 1.63 EPS for the current fiscal year.

Axon Enterprise News Summary

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Strong Q2 growth and higher outlook: Axon reported second-quarter revenue of approximately $904 million, up 35% year over year and above analyst expectations. The company raised its 2026 revenue-growth forecast to 32%–34%, citing record bookings, international expansion and demand for its connected devices and software. Axon Beat Estimates and Raised Guidance, Shares Dropped
• Positive Sentiment: AI and Dedrone momentum: AI Era revenue, including Draft One automated police-report software, grew nearly 700% from a year earlier. Dedrone counter-drone revenue exceeded $100 million, supported by deployments at all 11 World Cup sites, strengthening Axon’s long-term growth narrative. Axon Stock Falls After AI, Drone Wins Fuel Q2 Earnings Beat
• Positive Sentiment: Analyst and retail support: UBS raised its price target to $600 while maintaining a Neutral rating, and retail traders showed interest in buying the post-earnings pullback. William Blair also reiterated a Buy rating, highlighting recurring-revenue growth, counter-drone demand and Axon’s expanding AI platform. UBS Raises Axon Price Target
• Neutral Sentiment: Valuation remains elevated: Axon’s rapid share-price recovery has increased scrutiny of its valuation. Some analysis considers the stock expensive on discounted cash flow and only fairly valued on sales multiples, potentially limiting further gains unless growth remains strong. Axon Stock Could Be Overvalued
• Negative Sentiment: Margins and cash flow pressured the initial reaction: Software gross margin declined to 71.3% from 75.6%, while a greater mix of professional services, memory costs and investments in new products reduced profitability. Free cash flow also turned negative, and quarterly EPS was reported as slightly below some consensus estimates, prompting an initial post-earnings selloff. Axon Posts Lower Quarterly Gross Margin

Analyst Upgrades and Downgrades

AXON has been the topic of a number of research analyst reports. Barclays boosted their price target on Axon Enterprise from $523.00 to $688.00 and gave the company an “overweight” rating in a report on Thursday. Needham & Company LLC reaffirmed a “buy” rating on shares of Axon Enterprise in a research report on Thursday. TD Cowen restated a “buy” rating on shares of Axon Enterprise in a research report on Wednesday, July 22nd. Morgan Stanley boosted their price objective on shares of Axon Enterprise from $600.00 to $640.00 and gave the stock an “overweight” rating in a research note on Thursday. Finally, Royal Bank Of Canada reissued an “outperform” rating on shares of Axon Enterprise in a report on Tuesday, July 21st. Thirteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $730.92.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.